Alder reports positive top-line 24-week data demonstrating persistent migraine prevention
Alder BioPharmaceuticals announced top-line 24-week data demonstrating persistent migraine prevention in a Phase 2b clinical trial evaluating ALD403 in patients with chronic migraine. ALD403 is Alder's proprietary monoclonal antibody product candidate for migraine prevention that targets CGRP. July 25, 2016